Sarepta Therapeutics
S&P 600
$20.45
-0.34%
Delayed · cached 15 min
Peer comparison
| Company | Price↕ | Market Cap↕ | P/E↕ | P/B↕ | ROE %↕ | ROCE %↕ | Div yield %↕ | Valuation |
|---|---|---|---|---|---|---|---|---|
| AbbVie | $ 257.12 | $454.36B | 72.43 | -76.55 | -71.20 | 16.42 | 2.68 | — |
| Amgen | $ 377.35 | $204.01B | 23.42 | 17.45 | 65.97 | 12.94 | 2.56 | Above FV |
| Gilead Sciences | $ 143.72 | $178.21B | 21.20 | 15.08 | 71.94 | 26.69 | 2.22 | Above FV |
| Vertex Pharmaceuticals | $ 515.44 | $130.64B | 30.04 | 6.45 | 19.52 | 17.71 | 0.00 | Above FV |
| Regeneron Pharmaceuticals | $ 781.49 | $80.46B | 19.34 | 2.47 | 14.21 | 9.58 | 0.46 | Above FV |
| Moderna | $ 143.97 | $57.48B | -19.83 | 8.50 | -41.74 | -34.25 | 0.00 | — |
| Alnylam Pharmaceuticals, Inc. | $ 248.68 | $33.28B | 43.32 | 24.56 | 23.17 | 12.26 | 0.00 | Above FV |
| Biogen | $ 217.15 | $32.08B | 38.64 | 1.70 | 8.74 | 5.96 | 0.00 | Above FV |
| Insmed Incorporated | $ 129.41 | $28.26B | -20.16 | 37.29 | -181.14 | -77.58 | 0.00 | — |
| Incyte | $ 121.47 | $24.62B | 15.47 | 3.85 | 22.88 | 26.01 | 0.00 | Above FV |
| United Therapeutics | $ 497.11 | $21.32B | 17.82 | 3.31 | 20.85 | 22.41 | 0.00 | Above FV |
| Roivant Sciences | $ 40.82 | $29.49B | -75.59 | 6.97 | -7.08 | -10.25 | 0.00 | — |
Price, market cap, P/E, P/B and dividend yield reflect the live quote (delayed, cached 15 min); ROE/ROCE from reported financials. The highlighted row is the current company. Click a column header to sort. Educational data only.
How to read the peer comparison
This table places the company beside others in the same industry on a few common measures. Comparison adds context that a single company's numbers cannot give on their own.
- Valuation multiples like P/E and P/B are most meaningful within the same industry, because different industries naturally trade at different levels. Comparing a company only to its peers is more useful than to the whole market.
- Return measures (ROE, ROCE) show how efficiently each company turns capital into profit. A company well ahead of or behind its peers here is worth understanding.
- No single column decides anything. A beginner reads the row across — valuation, returns, and size together — and treats the highlighted current company as one data point among its peers.
- Use the sortable headers to rank peers on any measure, but remember that "cheaper" or "higher" on one metric is a starting question, not an answer.
Educational only — not a recommendation to buy, sell, or hold any security.